While I think something is brewing with Astex - I highly doubt this is it. Zantrene is hardly a commercial product and our collaboration isn't directly with Otsuka.
Worth noting that Astex is EU based and likely one of the reasons the EMD AML trial is expanding to Spain and Italy.
Ann: Race Develops Improved IV Formulation of Zantrene, page-73
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.055(3.79%) |
Mkt cap ! $237.8M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.33 | $213.7K | 155.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 7167 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |